» Articles » PMID: 35529078

Theranostic Biomaterials for Tissue Engineering

Overview
Date 2022 May 9
PMID 35529078
Authors
Affiliations
Soon will be listed here.
Abstract

Tissue engineering strategies, notably biomaterials, can be modularly designed and tuned to match specific patient needs. Although many challenges within tissue engineering remain, the incorporation of diagnostic strategies to create theranostic (combined therapy and diagnostic) biomaterials presents a unique platform to provide dual monitoring and treatment capabilities and advance the field toward personalized technologies. In this review, we summarize recent developments in this young field of regenerative theranostics and discuss the clinical potential and outlook of these systems from a tissue engineering perspective. As the need for precision and personalized medicines continues to increase to address diseases in all tissues in a patient-specific manner, we envision that such theranostic platforms can serve these needs.

Citing Articles

Implantation of engineered adipocytes suppresses tumor progression in cancer models.

Nguyen H, An K, Ito Y, Kharbikar B, Sheng R, Paredes B Nat Biotechnol. 2025; .

PMID: 39905264 DOI: 10.1038/s41587-024-02551-2.


Theranostic Applications of Scaffolds in Current Biomedical Research.

Patil S, Thorat V, Koparde A, Bhosale R, Bhinge S, Chavan D Cureus. 2024; 16(10):e71694.

PMID: 39559663 PMC: 11571282. DOI: 10.7759/cureus.71694.


Encapsulation of β-NGF in injectable microrods for localized delivery accelerates endochondral fracture repair.

Rivera K, Cuylear D, Duke V, OHara K, Zhong J, Elghazali N Front Bioeng Biotechnol. 2023; 11:1190371.

PMID: 37284244 PMC: 10241161. DOI: 10.3389/fbioe.2023.1190371.


Engineered Protein-Iron Oxide Hybrid Biomaterial for MRI-traceable Drug Encapsulation.

Hill L, Britton D, Jihad T, Punia K, Xie X, Delgado-Fukushima E Mol Syst Des Eng. 2023; 7(8):915-932.

PMID: 37274761 PMC: 10237276. DOI: 10.1039/d2me00002d.


Bone tissue engineering supported by bioprinted cell constructs with endothelial cell spheroids.

Kim W, Jang C, Kim G Theranostics. 2022; 12(12):5404-5417.

PMID: 35910797 PMC: 9330514. DOI: 10.7150/thno.74852.


References
1.
Collins F, Varmus H . A new initiative on precision medicine. N Engl J Med. 2015; 372(9):793-5. PMC: 5101938. DOI: 10.1056/NEJMp1500523. View

2.
Gormley C, Keenan B, Buczek-Thomas J, Pessoa A, Xu J, Monti F . Fibrin-Targeted Polymerized Shell Microbubbles as Potential Theranostic Agents for Surgical Adhesions. Langmuir. 2019; 35(31):10061-10067. PMC: 6767917. DOI: 10.1021/acs.langmuir.8b03692. View

3.
Zhang W, Yang G, Wang X, Jiang L, Jiang F, Li G . Magnetically Controlled Growth-Factor-Immobilized Multilayer Cell Sheets for Complex Tissue Regeneration. Adv Mater. 2017; 29(43). DOI: 10.1002/adma.201703795. View

4.
Mastrogiacomo S, Guvener N, Dou W, Alghamdi H, Camargo W, Cremers J . A theranostic dental pulp capping agent with improved MRI and CT contrast and biological properties. Acta Biomater. 2017; 62:340-351. DOI: 10.1016/j.actbio.2017.08.018. View

5.
Janke H, Guvener N, Dou W, Tiemessen D, Yantisetiasti A, Cremers J . Labeling of Collagen Type I Templates with a Naturally Derived Contrast Agent for Noninvasive MR Imaging in Soft Tissue Engineering. Adv Healthc Mater. 2018; 7(18):e1800605. DOI: 10.1002/adhm.201800605. View